1. A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection
- Author
-
Michelle Makiya, Amy D. Klion, Roshan Ramanathan, Nicole Holland-Thomas, Jennifer Stoddard, JeanAnne Ware, Jesica A. Herrick, Fanny Legrand, Thomas B. Nutman, Reagan H. Thompson, Shakuntala Rampertaap, and Michael P. Fay
- Subjects
Adult ,Microbiology (medical) ,medicine.medical_specialty ,Pilot Projects ,Antibodies, Monoclonal, Humanized ,Placebo ,Gastroenterology ,Diethylcarbamazine ,Loa ,Loiasis ,Double-Blind Method ,Reslizumab ,Internal medicine ,Eosinophilia ,Eosinophil activation ,medicine ,Animals ,Humans ,Adverse effect ,biology ,business.industry ,Eosinophil ,biology.organism_classification ,Infectious Diseases ,medicine.anatomical_structure ,Interleukin-5 ,medicine.symptom ,Loa loa ,business ,medicine.drug - Abstract
Background Diethylcarbamazine citrate (DEC) treatment of loiasis is complicated by adverse reactions that are correlated with the number of circulating microfilariae (mf). The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. Methods To explore the role of IL-5 driven eosinophilia in post-DEC reactions, 8 adults with confirmed loiasis and Results Baseline characteristics were comparable between the two groups. Single dose reslizumab lowered the AEC by 77% prior to initiation of DEC therapy (vs. 12% in the placebo group, P Conclusions In summary, although reslizumab was able to blunt peripheral eosinophilia post-DEC treatment in subjects with loiasis and had no effect on microfilarial clearance, the reduction in AEC appeared to have been insufficient to prevent post-treatment AEs.
- Published
- 2020